{"denoms":[{"counts":[{"groupId":"BG000","value":"39"}],"units":"Participants"}],"groups":[{"description":"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nbevacizumab: Given IV\n\nlenalidomide: Given orally\n\ndexamethasone: Given orally","id":"BG000","title":"Bevacizumab, Dexamethasone, and Lenalidomide"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"40-49 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"50-59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"60-69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"70-79 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"80-89 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}